Summary of Study ST000948
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000652. The data can be accessed directly via it's Project DOI: 10.21228/M8D38P This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000948 |
| Study Title | Mechanisms for Insulin Resistance in Polycystic Ovary Syndrome: aminoadipic acid, lysine concentrations, and enrichment (part II) |
| Study Summary | To determine how metformin therapy changes lysine and AAA kinetics in PCOS and whether this is associated with improvements in insulin sensitivity. Changes in lysine and AAA flux before and after three months of metformin therapy will be compared to women with PCOS randomized to no treatment for three months. |
| Institute | Mayo Clinic |
| Last Name | Chang |
| First Name | Alice |
| Address | 200 First St. SW, Rochester, Minnesota, 55905, USA |
| Chang.Alice1@mayo.edu | |
| Phone | 507-286-0505 |
| Submit Date | 2018-04-09 |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-04-13 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000652 |
| Project DOI: | doi: 10.21228/M8D38P |
| Project Title: | Mayo Pilot and Feasibility: Mechanisms for Insulin Resistance in Polycystic Ovary Syndrome |
| Project Summary: | Polycystic Ovary Syndrome (PCOS), a condition of androgen excess, infrequent ovulation, and insulin resistance is the most common endocrine disorder among premenopausal women. Little is known about the exact mechanisms of insulin resistance in PCOS and how metformin can improve insulin sensitivity, increase the frequency of ovulation and lower androgens in PCOS. Preliminary data from metabolomic analyses of amino acids demonstrate increased concentrations of lysine and its metabolite, α-aminoadipic acid (AAA), in PCOS versus obese controls. Interestingly, greater AAA concentrations predicted the development of type 2 diabetes in the Framingham epidemiologic cohort, experimentally lowers glucose in animal models and increases insulin secretion in vitro. To date, the mechanism for increased circulating concentrations of lysine and AAA in insulin-resistant individuals is not known. Building upon these findings, we have initiated a project to simultaneously study lysine and AAA kinetics for the first time in insulin-resistant individuals using stable isotope tracer methodology. We will evaluate: 1) whether lysine and AAA kinetics are altered in PCOS versus healthy controls; 2) the effect of hyperinsulinemia on lysine and AAA kinetics in PCOS versus controls; 3) whether treatment to improve insulin sensitivity changes lysine and AAA kinetics in PCOS. The long-term goal is to target pathways for the treatment of PCOS and the prevention of type 2 diabetes in PCOS and other insulin-resistant individuals at greater risk for type 2 diabetes. |
| Institute: | Mayo Clinic |
| Last Name: | Chang |
| First Name: | Alice |
| Address: | 200 First St. SW, Rochester, Minnesota, 55905, USA |
| Email: | Chang.Alice1@mayo.edu |
| Phone: | 507-286-0505 |
